Product Description
PTX-022 is a novel formulation of rapamycin which leverages Palvellas QTORIN technology.
Mechanisms of Action: TCR Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Palvella Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pachyonychia Congenita
Phase 2: Basal Cell Carcinoma|Basal Cell Nevus Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04893486 |
CODY | P2 |
Completed |
Basal Cell Nevus Syndrome|Basal Cell Carcinoma |
2023-03-13 |
12% |
2024-08-30 |
Primary Endpoints |
NCT05643872 |
PALV-08 | P3 |
Recruiting |
Pachyonychia Congenita |
2023-10-01 |
23% |
2025-08-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/12/2023 |
News Article |
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance |
|
05/28/2020 |
News Article |
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics |
|
05/06/2020 |
News Article |
Ligand Reports First Quarter 2020 Financial Results |
|
03/10/2020 |
News Article |
Ligand's Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com |